S&P 500   4,606.11 (+0.45%)
DOW   36,261.33 (+0.40%)
QQQ   392.35 (+0.49%)
AAPL   195.79 (+0.78%)
MSFT   373.71 (+0.74%)
META   331.79 (+1.59%)
GOOGL   135.14 (-1.31%)
AMZN   147.68 (+0.54%)
TSLA   244.56 (+0.79%)
NVDA   476.18 (+2.19%)
NIO   7.44 (-0.67%)
BABA   72.25 (-0.11%)
AMD   128.80 (+0.33%)
T   16.87 (-1.29%)
F   11.04 (+2.03%)
MU   75.20 (+2.10%)
CGC   0.80 (+10.13%)
GE   120.36 (+0.74%)
DIS   92.78 (+0.47%)
AMC   6.93 (+1.61%)
PFE   28.86 (+0.80%)
PYPL   58.97 (+0.84%)
XOM   99.32 (+0.91%)
S&P 500   4,606.11 (+0.45%)
DOW   36,261.33 (+0.40%)
QQQ   392.35 (+0.49%)
AAPL   195.79 (+0.78%)
MSFT   373.71 (+0.74%)
META   331.79 (+1.59%)
GOOGL   135.14 (-1.31%)
AMZN   147.68 (+0.54%)
TSLA   244.56 (+0.79%)
NVDA   476.18 (+2.19%)
NIO   7.44 (-0.67%)
BABA   72.25 (-0.11%)
AMD   128.80 (+0.33%)
T   16.87 (-1.29%)
F   11.04 (+2.03%)
MU   75.20 (+2.10%)
CGC   0.80 (+10.13%)
GE   120.36 (+0.74%)
DIS   92.78 (+0.47%)
AMC   6.93 (+1.61%)
PFE   28.86 (+0.80%)
PYPL   58.97 (+0.84%)
XOM   99.32 (+0.91%)
S&P 500   4,606.11 (+0.45%)
DOW   36,261.33 (+0.40%)
QQQ   392.35 (+0.49%)
AAPL   195.79 (+0.78%)
MSFT   373.71 (+0.74%)
META   331.79 (+1.59%)
GOOGL   135.14 (-1.31%)
AMZN   147.68 (+0.54%)
TSLA   244.56 (+0.79%)
NVDA   476.18 (+2.19%)
NIO   7.44 (-0.67%)
BABA   72.25 (-0.11%)
AMD   128.80 (+0.33%)
T   16.87 (-1.29%)
F   11.04 (+2.03%)
MU   75.20 (+2.10%)
CGC   0.80 (+10.13%)
GE   120.36 (+0.74%)
DIS   92.78 (+0.47%)
AMC   6.93 (+1.61%)
PFE   28.86 (+0.80%)
PYPL   58.97 (+0.84%)
XOM   99.32 (+0.91%)
S&P 500   4,606.11 (+0.45%)
DOW   36,261.33 (+0.40%)
QQQ   392.35 (+0.49%)
AAPL   195.79 (+0.78%)
MSFT   373.71 (+0.74%)
META   331.79 (+1.59%)
GOOGL   135.14 (-1.31%)
AMZN   147.68 (+0.54%)
TSLA   244.56 (+0.79%)
NVDA   476.18 (+2.19%)
NIO   7.44 (-0.67%)
BABA   72.25 (-0.11%)
AMD   128.80 (+0.33%)
T   16.87 (-1.29%)
F   11.04 (+2.03%)
MU   75.20 (+2.10%)
CGC   0.80 (+10.13%)
GE   120.36 (+0.74%)
DIS   92.78 (+0.47%)
AMC   6.93 (+1.61%)
PFE   28.86 (+0.80%)
PYPL   58.97 (+0.84%)
XOM   99.32 (+0.91%)

ProKidney Stock Price, News & Analysis (NASDAQ:PROK)

$1.83
+0.02 (+1.05%)
(As of 02:42 PM ET)
Compare
Today's Range
$1.71
$1.89
50-Day Range
$1.21
$4.76
52-Week Range
$1.12
$14.19
Volume
284,402 shs
Average Volume
460,843 shs
Market Capitalization
$430.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

ProKidney MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
747.0% Upside
$15.50 Price Target
Short Interest
Bearish
26.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$23.38 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.66) to ($0.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

828th out of 960 stocks

Biological Products, Except Diagnostic Industry

118th out of 135 stocks


PROK stock logo

About ProKidney Stock (NASDAQ:PROK)

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

PROK Stock Price History

PROK Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
ProKidney GAAP EPS of -$0.18
ProKidney Reports Third Quarter Financial Results
Power Player 2023: Tim Bertram, ProKidney
ProKidney 10% Owner Sold $1.21M In Company Stock
Why Shares of ProKidney Were Dropping Thursday
ProKidney 10% Owner Trades $9.30M In Company Stock
REACT Or Retreat: ProKidney's Phase 3 Focal Point
See More Headlines
Receive PROK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/26/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PROK
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.50
High Stock Price Target
$16.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+756.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-108,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($42.77) per share

Miscellaneous

Free Float
129,513,000
Market Cap
$426.14 million
Optionable
Not Optionable
Beta
0.81
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report














PROK Stock Analysis - Frequently Asked Questions

Should I buy or sell ProKidney stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PROK shares.
View PROK analyst ratings
or view top-rated stocks.

What is ProKidney's stock price target for 2024?

2 brokerages have issued 12-month target prices for ProKidney's shares. Their PROK share price targets range from $15.00 to $16.00. On average, they predict the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 747.0% from the stock's current price.
View analysts price targets for PROK
or view top-rated stocks among Wall Street analysts.

How have PROK shares performed in 2023?

ProKidney's stock was trading at $6.86 at the beginning of 2023. Since then, PROK shares have decreased by 73.3% and is now trading at $1.83.
View the best growth stocks for 2023 here
.

When is ProKidney's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our PROK earnings forecast
.

How were ProKidney's earnings last quarter?

ProKidney Corp. (NASDAQ:PROK) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.02.

What ETF holds ProKidney's stock ?

ALPS Medical Breakthroughs ETF holds 177,981 shares of PROK stock, representing 1.93% of its portfolio.

Who are ProKidney's major shareholders?

ProKidney's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Social Capital Group LLC (4.92%), Morgan Stanley (4.37%), Northern Trust Corp (0.16%), Charles Schwab Investment Management Inc. (0.11%), Bank of New York Mellon Corp (0.05%) and Rhumbline Advisers (0.03%).
View institutional ownership trends
.

How do I buy shares of ProKidney?

Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PROK) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -